Elon Musk bank-rolled a PAC that sought to link the now-President elect Trump's views on abortion with those of the late liberal Supreme Court Justice Ruth Bader Ginsburg, according to new campaign filings.
The big picture: Musk, who will co-lead the Department of Government Efficiency (DOGE) in the incoming adminstration, spent more than $250 million in total in donations to Trump's presidential campaign, per the New York Times.
A major health insurance company is backing off of a controversial plan to limit coverage of anesthesia, according to public officials.
Why it matters: Anthem Blue Cross Blue Shield recently decided to "no longer pay for anesthesia care if the surgery or procedure goes beyond an arbitrary time limit, regardless of how long the surgical procedure takes," according to the American Society of Anesthesiologists, which opposed the decision.
President-elect Trump hosted the chief executives of Pfizer, Eli Lilly and PhRMA Wednesday night at Mar-a-Lago, where they discussed how the public and private sectors can collaborate on finding cures for cancer, among other topics, Axios has learned.
Why it matters: The patio dinner is a potential indication that Trump's administration will see the pharmaceutical industry as a partner — not just an adversary — for parts of its "Make America Healthy Again" agenda.
Two private equity firms aided and abetted "egregious breaches" of fiduciary duty, a Delaware Chancery Court judge ruled earlier this week. And it could take a big bite out of their fund returns.
Why it matters: The judge's remedy is novel, and could become a blueprint for other courts.
Patients could get a better night's rest if hospitals changed how often staff check in on patients and deployed sleep tools, an investigation published Wednesday in JAMA Network Open found.
Why it matters: Lack of sleep is a ubiquitous problem among hospitalized patients and can impact their outcomes and satisfaction with care.
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from the first head-to-head trial comparing the two blockbuster GLP-1 obesity drugs.
Why it matters: The data, which hasn't been peer-reviewed, could give Lilly an added advantage in what's essentially a two-horse race for the booming weight-loss drug market.
Wednesday's shocking murder of UnitedHealthcare CEO Brian Thompson unleashed a wave of social media-fueled rage against health insurers, with posters lashing out over coverage denials and other business practices.
Why it matters: Experts say the lack of sympathy may reflect an inherent truth about Americans and their health plans: People tend to like their own insurer but distrust the industry — and indeed, the health system at large.
